{"classes":[{"categories":[{"measurements":[{"comment":"Medians were not reached for timeframe","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Medians were not reached for timeframe","groupId":"OG001","lowerLimit":"19.8","upperLimit":"NA","value":"NA"},{"comment":"Medians were not reached for timeframe","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"74"},{"groupId":"OG002","value":"72"}],"units":"Participants"}],"description":"Time to first SRE is defined as time from randomization to any one of the following related to multiple myeloma: New Pathological Fracture, Spinal Cord Compression, Surgery to the Bone, Radiation to the Bone collected until participant death, study closure or lost to follow up. Participants not known to have had an SRE at the time of the analysis were censored at the date of their last complete documented assessment for SRE.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 milligram per square meter (mg/m\\^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG000","title":"100 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG001","title":"300 mg Tabalumab+Dexamethasone+Bortezomib"},{"description":"Placebo administered once IV on Day 1 every 21 days for 8 cycles.\n\nDexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.\n\nBortezomib 1.3 mg/m\\^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.","id":"OG002","title":"Placebo Comparator: Placebo + Dexamethasone + Bortezomib"}],"paramType":"MEDIAN","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline to Date of First Skeletal Related Event (assessed up to 19 months)","title":"Time to First Skeletal-Related Event (SRE)","type":"SECONDARY","unitOfMeasure":"months"}